Stephen Devereux
#179,550
Most Influential Person Now
Researcher
Stephen Devereux's AcademicInfluence.com Rankings
Download Badge
Economics
Stephen Devereux's Degrees
- PhD Economics University of Oxford
- Bachelors Economics University of Oxford
Similar Degrees You Can Earn
Why Is Stephen Devereux Influential?
(Suggest an Edit or Addition)Stephen Devereux's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) (1363)
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. (2015) (1185)
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. (2016) (707)
- In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. (2000) (530)
- The PI3 kinase, p38 SAP kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte–derived dendritic cells (2000) (383)
- The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. (2000) (340)
- The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. (2000) (269)
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study (2019) (266)
- CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. (2008) (243)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. (2004) (201)
- Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF (1990) (195)
- Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. (2012) (184)
- BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. (2004) (171)
- Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. (2006) (165)
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study (2019) (150)
- Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. (1997) (150)
- Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. (2002) (126)
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies (2020) (117)
- Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma) (2011) (110)
- Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: in‐vitro and in‐vivo studies in man (1989) (106)
- Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. (2019) (105)
- Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. (2010) (103)
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 (2018) (102)
- Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP‐9 (2011) (89)
- Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens (2002) (88)
- Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. (2019) (78)
- CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. (2011) (75)
- Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. (1990) (74)
- Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. (2013) (71)
- TRANSIENT LEUCOPENIA INDUCED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (1987) (71)
- ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m−2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients (2000) (61)
- Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. (1998) (61)
- Mimicking the tumour microenvironment: three different co‐culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells (2012) (57)
- Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. (2007) (56)
- In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. (2001) (54)
- Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital. (2015) (52)
- Lamivudine prophylaxis and treatment of hepatitis B Virus‐exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab (2006) (51)
- Recombinant human granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double‐blind, placebo‐controlled trial (1992) (51)
- Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes (2006) (50)
- Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (2010) (49)
- Outcome of BEAM‐autologous and BEAM‐alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma (2008) (49)
- High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML (1999) (49)
- Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. (2013) (48)
- IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. (2005) (48)
- Granulocyte-macrophage colony-stimulating factor may inhibit neutrophil migration in vivo. (1989) (47)
- Heparin Binds to Murine Leukemia Virus and Inhibits Env-Independent Attachment and Infection (2002) (47)
- Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (2016) (45)
- Sclerodermatous graft‐versus‐host disease: clinical spectrum and therapeutic challenges (2007) (43)
- NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome (2016) (41)
- Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy (2017) (41)
- Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma (1998) (40)
- Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures (1997) (40)
- Tumor-derived IL-6 may contribute to the immunological defect in CLL (2008) (40)
- Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cell–Derived IFN-γ by a T-bet–Dependent Mechanism (2015) (39)
- Haemopoietic growth factors. (1990) (38)
- Delayed attainment of full donor chimaerism following alemtuzumab‐based reduced‐intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes (2007) (38)
- Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. (2014) (38)
- Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. (2021) (33)
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study (2017) (30)
- Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2018) (30)
- Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) (2006) (29)
- Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data (2007) (29)
- Best Practice in Lymphoma Diagnosis and Reporting (2012) (28)
- Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study (2018) (28)
- An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion (1999) (28)
- Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. (2016) (27)
- Secretion of neutrophil secondary granules occurs during granulocyte‐macrophage colony stimulating factor induced margination (1990) (27)
- Life-threatening motor neurotoxicity in association with bortezomib. (2006) (26)
- Dyskeratosis congenita with pancytopenia (1985) (26)
- Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2017) (26)
- Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. (2006) (25)
- Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions (2003) (25)
- Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. (2014) (24)
- Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells. (2018) (24)
- Platelet associated IgG and immune thrombocytopenia in lymphoproliferative and autoimmune disorders. (2008) (23)
- Antiapoptotic Microenvironment of Acute Myeloid Leukemia (2004) (23)
- Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition (2014) (22)
- The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. (2005) (22)
- Effect of changes in expression of the amphotropic retroviral receptor PiT-2 on transduction efficiency and viral titer: implications for gene therapy. (2000) (22)
- PNP with Waldenström's macroglobulinaemia (2005) (22)
- Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. (2007) (22)
- Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis (2019) (22)
- Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study (2018) (22)
- Fatal donor-derived Epstein–Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome (2002) (22)
- Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). (2012) (21)
- Effect of CD3/CD28 Bead-Activated and Expanded T Cells on Leukemic B Cells in Chronic Lymphocytic Leukemia (2005) (21)
- Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies (2018) (19)
- Clinical significance of the haemopoietic growth factors. (1989) (19)
- Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature (2007) (19)
- Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2014) (19)
- Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity (2017) (18)
- The upregulation of CC chemokine receptor 7 and the increased migration of maturing dendritic cells to macrophage inflammatory protein 3β and secondary lymphoid chemokine is mediated by the p38 stress‐activated protein kinase pathway (2002) (18)
- Cardiac presentation of ALK positive anaplastic large cell lymphoma (2005) (18)
- Immediate side effects of large fraction radiotherapy. (1997) (18)
- Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data. (2016) (17)
- Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival (2007) (17)
- Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. (2021) (17)
- A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. (2013) (16)
- Sarcoidosis and haematological malignancies: is there an association? (2008) (16)
- A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma (2018) (16)
- Therapy associated leukaemia. (1991) (16)
- Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial (2020) (15)
- Koebnerizing sclerodermatous graft‐versus‐host disease caused by donor lymphocyte infusion and interferon‐α (2006) (15)
- Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL). (2016) (15)
- Rhabdomyolysis and acute renal failure in sickle cell anaemia. (1985) (15)
- TRANSIENT LEUKOPENIA INDUCED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (1987) (14)
- Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability. (2020) (14)
- The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells (2019) (13)
- A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients. (1988) (12)
- Rhabdomyolysis and acute renal failure in sickle cell anaemia (1985) (11)
- ALK‐positive large B‐cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib (2016) (11)
- Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial (2015) (10)
- A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. (1999) (10)
- Two-faced T cells in CLL. (2011) (10)
- Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. (2014) (10)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. (2003) (10)
- A Clinically Applicable Method for the ex vivo Generation of Antigen–Presenting Cells from CD34+ Progenitors (1998) (9)
- Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H. (2001) (9)
- Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience (1998) (9)
- TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target. (2021) (9)
- The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (2018) (8)
- False positive results of galactomannan ELISA assay in haemato-oncology patients: a single centre experience. (2007) (8)
- Allogeneic stem cell transplantation (SCT) in MDS: Interim results of outcome following non-myeloablative conditioning compared to standard preparative regimens. (2000) (8)
- The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile (2015) (8)
- Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids (2017) (8)
- Storage of PBSC at -80°C (1998) (8)
- Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study (2017) (8)
- Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia (2014) (8)
- Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison (2017) (8)
- CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT (2014) (8)
- Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (2016) (8)
- Simultaneous occurrence of Clostridium difficile and Cytomegalovirus colitis in a recipient of autologous stem cell transplantation. (2000) (8)
- Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study (2017) (7)
- Imatinib mesylate in myelofibrosis: Preliminary results show early sustained improvements in platelet counts and splenomegaly. (2002) (7)
- Primary effusion lymphoma in an HIV‐negative man (2011) (7)
- Analysis of mutations in the GM-CSF receptor alpha coding sequence in patients with acute myeloid leukaemia and haematologically normal individuals by RT-PCR-SSCP. (1994) (6)
- Increase in allergy following donor lymphocyte infusions (2006) (6)
- In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia (2017) (6)
- Factor VIII inhibitor and raised platelet IgG levels associated with methyldopa therapy (1983) (6)
- A retrospective analysis of post‐transplant lymphoproliferative disorder following liver transplantation (2018) (5)
- Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience. (2011) (5)
- Fc gamma RII-mediated superoxide production by phagocytes is augmented by GM-CSF without a change in Fc gamma RII expression. (1990) (5)
- Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure (2018) (5)
- Anti-sense and gene therapy approaches to the treatment of lymphomas. (1996) (5)
- Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM)) (2015) (5)
- The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma (2017) (5)
- Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2) (2016) (5)
- How I treat patients with relapsed chronic lymphocytic leukaemia (2013) (5)
- Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. (2014) (5)
- Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features (2022) (4)
- Reduced-intensity allogeneic haematopoietic stem cell transplantation(HSCT) in 75 patients with myelodysplastic syndromes following conditioning with fludarabine, busulphan and alemtuzumab. (2003) (4)
- Non-myeloablative conditioning limits transplant related mortality in patients who have previously failed high dose treatment. (2000) (4)
- Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2017) (3)
- The effects of recombinant human granulocyte-macrophage colony-stimulating factor on phagocyte kinetics in man. (1988) (3)
- Garanulocyte-macrophage colony-stimulating factor (1990) (3)
- Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI. (2005) (3)
- A NOVEL ISOFORM OF THE LOW-AFFINITY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR (1993) (3)
- CD38 expression in B-CLL is dynamic and changes due to contact with activating stimuli found within the leukaemic microenvironment (2006) (3)
- Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™) (2016) (3)
- Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy (2006) (3)
- FcRll-Mediated Superoxide Production by Phagocytes Is Augmented by GM-CSF Without a Change in FcyRIl Expression (1990) (3)
- In-Vivo Labelling Studies in Patients with Chronic Lymphocytic Leukemia Studies Demonstrate the Existence of Apparently Distinct Subpopulations That Differ in Phenotype and Proliferative Capacity (2015) (2)
- Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study (2016) (2)
- Multiparameter Microscopy Analysis of the Follicular Lymphoma Microenvironment and Normal Germinal Centers: In Vivo evidence That Follicular Helper T Cells Form Synapses with Neoplastic B Cells and Are Associated with Proliferation and Expression of Activation Induced Cytidine Deaminase (2014) (2)
- IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes. (2006) (2)
- Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate. (2004) (2)
- Use of the galactomannan ELISA in the detection of invasive aspergillosis: a retrospective review and potential pitfalls in application (2004) (2)
- SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME (2015) (2)
- IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML (2004) (2)
- Granulocyte‐macrophage colony stimulating factor receptor α and β chain complexes can form both high and intermediate affinity functional receptors (1997) (2)
- MOBILISATION FAILURE IS PREDICTIVE OF POOR OVERALL SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION (2008) (2)
- Reduced intensity conditioned volunteer unrelated donor transplants using alemtuzumab are safe and effective in older patients with myelodysplastic syndromes (2005) (2)
- Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium (2013) (2)
- Analysis of BEAM (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) versus high dose Melphalan (HDM) with autologous rescue in multiple myeloma(MM) (2004) (2)
- The PI 3 kinase , p 38 SAP kinase , and NFk B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte – derived dendritic cells (2)
- Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial (2019) (2)
- THE USE OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR TO ACCELERATE RECOVERY OF THE AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN MAN (1988) (2)
- Storage of PBSC at -80 degrees C. (1998) (2)
- Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study (2019) (2)
- Backup bone marrow is frequently ineffective in patients with poor peripheral blood progenitor cell mobilization. (1997) (1)
- Reduced-intensity rituximab-BEAM-CAMPATH allogeneic transplantation for indolent non-Hodgkin's lymphoma. (2001) (1)
- Restricted MHC Phenotypes in Lymphoproliferative Disorders with Non-Random Immunoglobulin Variable Gene Usage: Evidence for Antigen-Specific Interactions between Tumor and Microenvironment. (2006) (1)
- Alemtuzumab containing reduced intensity conditioning regimen is safe and effective in myelofibrosis. (2003) (1)
- Incidence and management of veno-occlusive disease following reduced-intensity conditioning haematopoietic stem cell transplantation (2006) (1)
- Laser capture microscopy as a tool for the assessment of lineage‐specific chimaerism from archived blood and bone marrow films (2007) (1)
- RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA: RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL (2014) (1)
- The retinoblastoma family member, p107, is active in non‐dividing monocyte‐derived dendritic cells (2001) (1)
- S107 FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (1)
- CLINICAL-SIGNIFICANCE OF THE HEMATOPOIETIC GROWTH-FACTORS (1989) (1)
- 2.50 CLL Lymph Node T-Cells Show Evidence of Chronic Antigenic Stimulation and a Skewed T-Cell Receptor Repertoire (2011) (1)
- Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease. (2007) (1)
- CAMPATH-1H reduces the risk of graft versus host disease following allogeneic hematopoietic stem cell transplantation and minimally myelosuppressive conditioning treatment with low dose total body irradiation and Cyclosporine/Mycophenotate Mofetil immunosuppression. (2001) (1)
- Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML (2011) (1)
- Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently (2005) (1)
- Analysis Of T Cell Receptor Repertoire Reveals Evidence For Antigen-Specific Response In CLL Lymph Nodes (2013) (1)
- Lymphoma diagnosis: an update. (2007) (1)
- Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT). (2005) (1)
- Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML). (2005) (1)
- MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study (2022) (1)
- Calcium RasGRP 2 Rap 1 signaling mediates CD 38 induced migration of chronic lymphocytic leukemia cells (2018) (1)
- Direct Evidence for a Chronic Antigen Driven T Cell Response In CLL Lymph Nodes (2010) (1)
- Adenovirus infections following allogeneic HSCT. A single UK centre experience (2007) (1)
- Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors. (2005) (1)
- A Clinically Applicable Method for the ex vivo Generation of Antigen‐Presenting Cells from CD34+ Progenitors (2000) (1)
- Haematologic and immunologic function and patient-reported outcomes for the phase 3 RESONATE (TM) study of ibrutinib versus ofatumumab in relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (2015) (1)
- Corrigendum to “Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation” [Journal of Infection 54 (2007) e83–e86] (2007) (1)
- Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma. (2006) (1)
- HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS (2012) (1)
- Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL (2008) (1)
- Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege (2015) (1)
- Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT). (2004) (1)
- Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. (2004) (1)
- Results of alemtuzumab-based reduced-intensity allogeneic transplantation for advanced chronic lymphocytic leukaemia: a BSBMT study (2005) (1)
- Reduced intensity allogeneic transplantation using BEAM-Campath in patients with lymphoproliferative disease-GVHD, toxicity and survival in 65 patients. (2002) (1)
- Haemophagocytic lymphohistiocytosis (HLH) following orthotopic liver transplantation: a single centre report of 37 cases (2006) (1)
- Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes (2011) (0)
- patients for lymphoproliferative diseases: GVHD, toxicity and survival in 65 BEAM-Campath reduced intensity allogeneic stem cell transplantation (2013) (0)
- Uncoupling of BCR Internalization and Signaling in Treatment Naive and Btki-Treated Patients with Chronic Lymphocytic Leukemia (2016) (0)
- THE MECHANISM OF GM-CSF INDUCED NEUTROPENIA (1988) (0)
- Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation (2014) (0)
- PRELIMINARY STUDIES OF RECOMBINANT GM-CSF IN MAN (1988) (0)
- Mono- and biclonal gammopathies following conditioning regimens incorporating alemtuzumab for haemopoietic stem cell transplantation (2003) (0)
- Multi-drug resistance (MDR-1) gene transfer in patients with poor prognosis lymphoma undergoing high dose therapy and CD34 selected peripheral blood stem cell transplantation (PBSCT) (1999) (0)
- The inhibitory effects of multiple tumor derived soluble factors on apoptosis and T cell function in the leukemic microenvironment. (2002) (0)
- Granulocyte-macrophage colony-stimulating factor (1990) (0)
- In vitro and in vivo evidence for uncoupling of BCR internalization and signaling in chronic lymphocytic leukemia (2017) (0)
- Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma (2012) (0)
- Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples (2017) (0)
- Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL (2022) (0)
- Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2016) (0)
- Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report. (2005) (0)
- The p38 stress activated protein kinase mediates the increased responsiveness of mature dendritic cells to macrophage inhibitory protein 3 beta (MIP3 beta) and secondary lymphoid chemokine (SLC). (2000) (0)
- CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) (2021) (0)
- The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML. (2006) (0)
- Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML. (2012) (0)
- IL-2/B7.1 (CD80) fusagene transduction of AML blastsby a self-inactivating lentiviral vector (2005) (0)
- A Ibrutinib results in reduction of phosphorylation of multiple kinases in the B-Cell receptor pathway in chronic lymphocytic leukaemia (Cll): results of the Bloodwise Tap Iciclle study (2017) (0)
- Short tandem repeat analysis on microdissected samples of explant liver tissue after hepatocyte transplantation (2007) (0)
- Retrospective review of prophylaxis for toxoplasmosis following allogeneic bone marrow transplantation (2005) (0)
- A single centre experience of reduced intensity conditioned HSCT using BEAM-campath for low-grade lymphoid malignancies (2004) (0)
- PHASE-I PHASE-II STUDIES OF RH GM-CSF AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE (1988) (0)
- Outcome of BEAM autotransplantation in patients with Hodgkin's disease progressing on first line therapy is the same as in patients transplanted in first partial remission. (1997) (0)
- Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr). (2018) (0)
- Retrospective analysis of the use of valganciclovir in the prevention of cytomegalovirus following stem cell transplantation (2004) (0)
- The acquired CD40 ligand deficiency observed in patients with B-CLL is reversible and due to soluble leukaemia derived factor(s) (2004) (0)
- Immunoregulatory properties of B-CLL cells (2005) (0)
- nejmoa1509981 appendix (1) (2016) (0)
- Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients (2006) (0)
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis (2019) (0)
- Activation of the stat 5 and MAP kinase signalling pathways by high and intermediate affinity GM-CSF receptors. (1996) (0)
- Cell Therapy (1997) (0)
- A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma (2018) (0)
- Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study (2020) (0)
- Improved outcome following reduced intensity conditioned allogeneic haematopoietic stem cell transplantation compared with myeloablative conditioning for acute myeloid leukaemia (2006) (0)
- Depletion of dendritic cells (DCs) from the blood and skin of patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT) by alemtuzumab containing regimens. (2002) (0)
- Monocyte derived dendritic cells do not proliferate and are refractory to transduction by retroviral vectors. (1998) (0)
- Chronic lymphocytic leukaemia lymph node T-cells show evidence of chronic antigenic stimulation (2011) (0)
- Age over 60 is not a barrier for successful autologous stem cell transplantation in selected patients with lymphoma: A single institution's experience in 37 consecutive patients. (1999) (0)
- raction with Vascular Endothelium Enhances Survival in ary Chronic Lymphocytic Leukemia Cells via NF-κB (2010) (0)
- LeukaemiasChronic lymphocytic leukaemia (2017) (0)
- Safety considerations of a new anti-CMV cellular therapy - experience from donor-derived, directly selected, adoptively transferred T cells (Cytovir (TM) CMV) in 2 randomized clinical trials (2015) (0)
- 1131. Generation of Whole Cell Vaccines for Acute Myeloid Leukaemia by Lentivirus Mediated IL-2/CD80 Transduction (2005) (0)
- The outcome of lymphoproliferative disorder in liver transplant recipients may correlate with age at diagnosis and the use of chemotherapy: A single centre report (2005) (0)
- Development of a semi-quantitative method for obtaining chimerism data from tissue and archived material (2005) (0)
- Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population (2014) (0)
- Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data. (2004) (0)
- The acquired CD40L deficiency in B-CLL is reversible and due to contact dependant and independent factors (2004) (0)
- ANALYSIS OF MUTATIONS IN THE GM-CSF RECEPTOR-ALPHA GENE IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA (1993) (0)
- G-banded cytogenetics from CpG oligonucleotide and IL-2 stimulated CLL peripheral blood cultures (2008) (0)
- HLA-DR associations and cell contact implicate specific T-cell responses in the pathogenesis of splenic marginal zone lymphoma (2007) (0)
- Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI). (2007) (0)
- CD38 expression in B-CLL is dynamic and influenced by cell contact in the leukaemic microenvironment (2007) (0)
- MDS myelodysplastic syndromes and acute myeloid leukemia secondary to related proteins in the - The role of apoptosis, proliferation, and the Bcl-2 (2013) (0)
- Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation. (2007) (0)
- Liver function abnormalities following alemtuzumab (Campath-1H): A previously unrecognised first dose effect (2005) (0)
- tumor microenvironment CD38 expression in chronic lymphocytic leukemia is regulated by the (2013) (0)
- B-CLL cells secrete factors including IL-6 which inhibit T cell proliferation and activation and promote Th2 polarisation (2007) (0)
- Evaluation of clinical scale CD34+cell purification devices (1999) (0)
- CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse (2015) (0)
- Chemokine signaling and traffi cking of B-cells and chronic lymphocytic leukemia cells (2014) (0)
- p38 stress-activated protein kinase and NF-kappa B activity are required for lipopolysaccharide-induced maturation of monocyte-derived dendritic cells. (1999) (0)
- Graft-versus-host disease (1997) (0)
- Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation. (1999) (0)
- In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning. (2007) (0)
- Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data (2016) (0)
- Engraftment of donor langerhans cells following allogeneic stem cell transplantation with reduced intensity conditioning (RIC) is delayed compared to other myeloid lineages (2007) (0)
- 2.42 Mimicking the Tumor Microenvironment: Three Different Co-culture Systems Induce a Similar Phenotype but Different Proliferative Signals in Primary Chronic Lymphocytic Leukemia Cells (2011) (0)
- Chronic Lymphocytic Leukemia Expanded T Cells on Leukemic B Cells in Effect of CD3/CD28 Bead-Activated and (2013) (0)
- Generalized eczematoid graft-versus-host disease: presentation, natural history, and treatment (2005) (0)
- Evidence for A Macromolecular Complex in Poor Prognostic CLL That Contains CD38, CD49d, CD44, MMP-9 and ZAP-70 (2009) (0)
- A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab. (2009) (0)
- Generation of functionally competent antigen presenting cells from CD34+ progenitors suitable for clinical use. (1998) (0)
- Two Distinct Co-Culture Systems, Designed to Mimic the Tumor Microenvironment, Induce Remarkably Similar Phenotypic Changes in Primary CLL Cells (2009) (0)
- Derived IFN- - Express CD38 in Response to Th1 Cell Chronic Lymphocytic Leukemia Cells (2015) (0)
- Evidence for a macromolecular complex in poor prognostic chronic lymphocytic leukaemia (CLL) that contains CD38, CD49d, CD44, MMP-9 And ZAP-70 (2010) (0)
- Hematopoietic growth factors (2004) (0)
- Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: a single institution experience (2006) (0)
- P38 stress-activated protein kinase activity is required for the lipopolysaccharide-induced maturation of monocyte-derived dendritic cells. (1999) (0)
- Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival. (2005) (0)
- Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS. (2005) (0)
- Use of autologous bone marrow harvests in patients undergoing volunteer unrelated donor stem cell transplantation: a single-centre experience (2007) (0)
- Targeting The T Cell Component Of The Tumour Microenvironment In Chronic Lymphocytic Leukaemia; A Potential Therapeutic Strategy (2013) (0)
- CD38 expression in B-CLL is not fixed and may change due to contact with activating stimuli found within the leukaemic microenvironment (2005) (0)
- Audit of central nervous system (CNS) prophylaxis in patient with diffuse large B-cell lymphoma (DLBCL) (2015) (0)
- The effect of the B-CLL microenvironment on CD38 expression by the malignant clone (2007) (0)
- Cancer esearch cular and Cellular Pathobiology raction with Vascular Endothelium Enhances Survival in ary Chronic Lymphocytic Leukemia Cells via NF-κ B R ivation and De novo Gene Transcription (2010) (0)
- LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE (2016) (0)
- Granulocyte macrophage colony stimulating factor (2012) (0)
- International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)) (2016) (0)
- PS1304 FOLLICULAR HELPER T-CELLS FORM MUTUALLY SUPPORTIVE INTERACTIONS WITH FOLLICULAR LYMPHOMA B-CELLS THAT MAY SUPPORT TUMOUR GROWTH (2019) (0)
- Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia (2019) (0)
- nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following (2013) (0)
- Granulocyte-macrophage colony stimulating factor receptor alpha and beta chain complexes can form both high and intermediate affinity functional receptors. (1997) (0)
- Myeloid Leukemia Antiapoptotic Microenvironment of Acute (2004) (0)
- An insertion in the extracellular domain of the human GM-CSF receptor alpha subunit reduces surface expression by a post-translational mechanism. (1996) (0)
- In-vivo studies of trafficking in chronic lymphocytic leukaemia provide definitive evidence of re-entry into the lymph-node compartment and suggest the existence of a quiescent sub-clone (2015) (0)
- Cytogenetic characterisation in a patient with concomitant multiple myeloma and CLL (2008) (0)
- Characterisation of a dynamicin vitrocirculation system designed to model the interaction between primary CLL cells and endothelial cells in the peripheral vasculature (2013) (0)
- Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML). (2006) (0)
- Receptor binding is a limiting factor in the transduction of CD34(+) hematopoietic cells with amphotropic retroviral vectors. (1997) (0)
- Response to Peggs et al. (2003) (0)
- Older age is not a barrier to successful allogeneic BMT. (1999) (0)
- Invasive pulmonary aspergillosis is not a contraindication to reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation (RIC allo-HSCT) (2004) (0)
- Generalized eczematoid graft-vs.-host disease: presentation and natural history (2005) (0)
- Granulocyte-macrophage colony-stimulating factor (1990) (0)
- Chronic lymphocytic leukaemia (2013) (0)
- Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood (2013) (0)
- Isoforms of the granulocyte : macrophage colony stimulating factor receptor. (2010) (0)
- Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2020) (0)
- Proliferative capacity and susceptibility to retroviral transduction of CD34 and monocyte derived dendritic cells. (1999) (0)
- Association of sarcoidosis with haematological malignancies and secondary dysplastic features. A single centre experience (2006) (0)
- Retrospective review of patients with high risk of HBV disease undergoing reduced intensity conditioned (RIC) allogeneic BMT (2005) (0)
- Impact of non-myeloablative conditioning on the frequency of second donation: what should donors be told? (2007) (0)
- Improved disease free survival following reduced intensity conditioned allogeneic stem cell transplantation incorporating alemtuzumab compared with autologous stem cell transplantation in follicular lymphoma (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephen Devereux?
Stephen Devereux is affiliated with the following schools:
